STRICTLY CONFIDENTIAL AND NOT FOR DISTRIBUTION

TRIVARIATE RESEARCH

THE CASE FOR OWNING HEALTHCARE RIGHT NOW

ADAM S. PARKER, Ph.D., FOUNDER
adam@trivariateresearch.com
646-734-7070

CHANG GE, ANALYST
chang@trivariateresearch.com
614-397-0038

MAXWELL ARNOLD, ANALYST
maxwell@trivariateresearch.com
347-514-1234

RYAN MCGOVERN, DIR. OF RESEARCH SALES
ryan@trivariateresearch.com
973-271-8017

COLIN COONEY, HEAD OF SALES
colin@trivariateresearch.com
617-910-7934

RESEARCH SUMMARY AND CONCLUSIONS

Background: For the last year, we have been recommending Healthcare stocks. The call has not been great. Over the last three months however, Pharma. / Biotech. / Lifesciences has been the 5th best of the GICS 25 industries, and Healthcare Equipment Services the 7th best. In today's note, we again make the case for being bullish on the sector. What are the reasons to own Healthcare?

1) Estimate achievability is above average, and revenue growth is steady.
2) Earnings are forecasted to grow in all Healthcare sub-industries, with potentially low expectations in Managed Care.
3) AI productivity will drive efficiencies in Healthcare more than other sectors, given the number of Healthcare employees, and below peak margins.
4) Healthcare is a top 3 M&A sector YTD. That will raise the floor valuations for several assets.
5) Healthcare is not correlated to AI Semiconductors, so it is portfolio diversifying, an important sector attribute as the S&P500 has essentially become an AI index.
6) Alpha generation is higher in Healthcare than other sectors, meaning stock pickers should spend time in Healthcare, though sub-industry neutral makes no sense in Healthcare.

And this all comes with valuation that on a relative basis appears to have troughed as the RFK Jr. discount has peaked.

For stock selection, we recommend focusing on companies with high forecasted sales growth, limited inventory-to-sales, among other factors. For quantitatively-derived long and short ideas in Healthcare, see Slides 16 and 17.

50% OF HEALTHCARE IS SOMETHING OTHER THAN PHARMA / BIOTECH.

Healthcare is a diverse sector with 10 sub-industries. Just over half of the market cap. of the Healthcare sector is 34% Pharmaceuticals and 19% Biotechnology among the mega-/large-cap. universe, with several smaller but differentiated segments (left) including Healthcare Equipment (20%), Life Sciences and Tools (9%) and Managed Care (8%). The mid-/small-cap. universe has some material differences, with Biotechnology (35%) and 9% Pharma (9%), with Healthcare Equipment (16%) and Life Sciences and Tools a much higher proportion of the SMID universe (15%) – see pie chart on right.

Mega / Large Cap. Healthcare by Sub-Industry
Distribution of Market Capitalization
End-October, 2024



Source: Trivariate Research

SMID Cap. Healthcare by Sub-Industry
Distribution of Market Capitalization
End-October, 2024



Source: Trivariate Research

SECTOR-WIDE ANALYSES ARE SKEWED BY MICRO-CAP BIOTECHS

The challenge with making broad sector comments on the Healthcare universe is that there are very disparate businesses, and many micro-cap stocks. Every single mega-/large-cap. Healthcare stock is forecasted to make money over the next 12 months except one Biotechnology company (left). On the contrary, several SMID cap. (right) Healthcare companies are forecasted to lose money, including 73% of the SMID Cap. Biotechnology sub-industry. Hence, when aggregating Healthcare data, considering the size and sub-industry is crucial.

Mega / Large Cap Healthcare
% with Positive Forward Earnings by Sector
As of End-October, 2025

Sub-Industry	Number of Stocks	% of Universe Market Cap.	% with Positive Forward Earnings
Pharmaceuticals	6	34%	100%
Healthcare Equipment	9	20%	100%
Biotechnology	7	19%	86%
Life Sciences Tools & Services	4	9%	100%
Managed Healthcare	2	8%	100%
Healthcare Distributors	3	4%	100%
Healthcare Services	2	3%	100%
Healthcare Facilities	1	2%	100%
Healthcare Technology	1	1%	100%

Source: Trivariate Research

SMID Cap. Healthcare
% with Positive Forward Earnings by Sector
As of End-October, 2025

Sector	Number of Stocks	% of Universe Market Cap.	% with Positive Forward Earnings
Biotechnology	102	35%	27%
Healthcare Equipment	32	16%	80%
Life Sciences Tools & Services	21	15%	85%
Pharmaceuticals	39	9%	67%
Healthcare Services	19	8%	94%
Managed Healthcare	7	5%	100%
Healthcare Facilities	12	5%	100%
Healthcare Supplies	13	4%	92%
Healthcare Technology	8	2%	83%
Healthcare Distributors	2	1%	100%

Source: Trivariate Research

HEALTHCARE EARNINGS HAVE STEADY GROWTH AND LESS VOL.

We analyzed the cyclicality of each sector's EPS growth, and concluded that the volatility of Healthcare earnings, despite some headline disappointments in well-known stocks this last week, like Zoetis (ZTS) and ZImmerBiomet (ZBH), is well below average. In fact, the volatility of EPS is only larger in Consumer Staples and Utilities over the last quarter century (left). S&P 500 Healthcare revenue per share is also very steady, having grown every year for more than 20 years in a row even during the Financial Crisis and COVID. The fact is, the US has many older Americans who demand Services, Tool, Diagnostics, and Drugs, driving above average estimate achievability.

Standard Deviation of YoY Quarterly EPS Log-Growth
2004 to 2026E



Source: Trivariate Research

Healthcare
Bottom-up Consensus Revenue Growth Per Share
Through 2026E
As of October 31, 2025



Source: Trivariate Research

EARNINGS ARE FORECASTED TO GROW ACROSS ALL SUB-INDUSTRIES

Net income growth is projected to be positive across the board in 2026, following growth in all but Healthcare Supplies and Managed Care in 2025. Biotech., Distributors, Technology and Equipment are all forecasted to have double-digit EPS growth next year. EPS expectations appear quite low off a new suppressed base in Managed Care.

Bottom-Up Analyst Net Income Growth Expectations by Healthcare Sub-Industry, Top 1,000 US Equities
November 6th, 2025

Sub-Industry	2024	2025E	2026E	Largest 3 Tickers
Biotechnology	(14.2%)	27.7%	25.2%	ABBV, AMGN, GILD
Health Care Distributors	4.1%	13.8%	13.2%	MCK, COR, CAH
Health Care Technology	55.4%	22.5%	12.3%	VEEV, DOCS, WAY
Health Care Equipment	8.6%	9.0%	10.2%	ABT, ISRG, BSX
Pharmaceuticals	19.9%	29.2%	8.2%	LLY, JNJ, MRK
Life Sciences Tools & Services	0.4%	2.2%	7.5%	TMO, DHR, A
Health Care Supplies	97.7%	(0.2%)	6.6%	COO, SOLV, ALGN
Health Care Services	(16.5%)	11.6%	5.2%	CVS, CI, LH
Health Care Facilities	19.4%	18.5%	2.9%	HCA, THC, UHS
Managed Health Care	2.4%	(36.8%)	1.9%	UNH, ELV, HUM

Source: Trivariate Research

HEALTHCARE COULD BE A MAJOR BENEFICIARY OF AI PRODUCTIVITY

There are a number of ways that AI productivity could benefit the Healthcare sector. This is from Nvidia's (NVDA) website: "NVIDIA is advancing healthcare with AI across science, robotics, and intelligent agents. From lab research and genomics to diagnostic imaging and patient engagement, our ecosystem empowers partners to accelerate discovery, improve care, and drive innovation with scalable, high-performance solutions." We offer some obvious areas of benefits (left). On the right, we show large Healthcare companies, with a large number of employees in absolute terms, who also have below peak net margins. Here we posit margin expansion is possible, as the management teams of the companies likely deploy tools to predict customer and employee behaviors and drive efficiencies.

We Think Healthcare Could Be a Big Area for AI Benefits:

- Data entry and HR onboarding, but also Healthcare intake information, legal review, customer service, predicting employee behavior, etc.
- Optimization: Closing the time gap between production and consumption to optimize inventory, factory productivity and downtime.
- Labor support: AI can help researchers, marketers, and designers be more productive without retraining costs by observing and evaluating in real-time and creating efficiencies. This increases revenue per employee.
- Task automation (no more clipboards at the Dr's office)
- AI-assisted diagnostics
- Drug discovery

Source: Trivariate Research

Candidate Healthcare Companies for AI-Driven Margin Expansion
High Number of Employees, Low Margin
End-October, 2025

Ticker	Company	Sub-Industry	Number of Employees	Market Cap. (US $Bil.)
ABBV	AbbVie Inc.	Biotechnology	55,000	383.12
UNH	UnitedHealth Group Incorporated	Managed Health Care	400,000	296.88
BDX	Becton, Dickinson and Company	Health Care Equipment	74,000	50.56
IQV	IQVIA Holdings Inc.	Life Sciences Tools & Services	88,000	35.78
LH	Labcorp Holdings Inc.	Health Care Services	70,000	20.78
DGX	Quest Diagnostics Incorporated	Health Care Services	56,000	19.83
ICLR	ICON Public Limited Company	Life Sciences Tools & Services	41,900	12.50
SOLV	Solventum Corporation	Health Care Supplies	22,000	11.74
RVTY	Revvity, Inc.	Life Sciences Tools & Services	11,000	10.50
HSIC	Henry Schein, Inc.	Health Care Distributors	25,000	8.54
TFX	Teleflex Incorporated	Health Care Equipment	14,100	5.51

Source: Trivariate Research

M&A SHOULD BE A BIG POSITIVE FOR HEALTHCARE IN 2026

Part of the bull case for Healthcare is that it is a potential beneficiary of increased M&A. Typically, 5.5% of the Healthcare stocks in the top 3000 by market capitalization receive a tender offer every 12-month period (left). That makes Healthcare a top three sector for M&A (right). In our view, it is incongruous to bid up the Investment Banking stocks – as we have seen since the Red Sweep – and not conclude that the valuations of select Healthcare stocks will also begin to expand. Recent offers announced include Novo Nordisk (NVO) acquiring Metsera (MTSR) and Akero (AKO), Alkermes (ALKS) acquiring Avadel (AVDL), Blackstone (BX) and Abu Dhabi acquiring Hologic (HOLX), and Biocryst (BCRX), among others.

Number of Acquisition Offerings
Healthcare Sector, Top 3000 US Equities
Through End-October, 2025



Source: Trivariate Research

% of Companies that Receive an Acquisition Offer
Mean of Each Year, Top 1000 US Equities
1999 to End-October, 2025



Source: Trivariate Research

HEALTHCARE HAS A LOW CORRELATION TO AI SEMICONDUCTORS

The S&P500 is an AI Semiconductors index, and hence, diversification and risk management are crucial – and an enormous part of our weekly work. The correlation of the overall Healthcare sector to our AI Semiconductors basket is relatively low at 0.47 (left). At the sub-industry level, Pharma, Healthcare Providers & Services, Healthcare Technology, and Biotechnology are all particularly diversifying (right).

126-Day Correlation of AI Semis by Sector
As of November 5th, 2025

Sector	Correlation	Percentile Rank vs. History (Since 2017)
Consumer Staples	16%	1%
Utilities	16%	20%
Real Estate	28%	26%
Financials	41%	22%
Healthcare	47%	15%
Energy	48%	41%
Consumer Discretionary	50%	15%
Communication Services	50%	23%
Materials	51%	21%
Industrials	63%	31%
Information Technology	76%	13%

Source: Trivariate Research

126-Day Correlation of AI Semis by Healthcare Industry
As of November 5th, 2025

Industry	Correlation	Percentile Rank vs. History (Since 2017)	Percentile Rank vs. All Industries
Pharmaceuticals	35%	10%	35%
Healthcare Providers & Services	37%	14%	37%
Healthcare Technology	39%	7%	44%
Biotechnology	41%	14%	50%
Healthcare Equipment & Supplies	46%	10%	61%
Life Sciences Tools & Services	49%	17%	68%

Source: Trivariate Research

HEALTHCARE HAS HIGH ALPHA GENERATION POTENTIAL

We have a proprietary 7-factor model that calculates how much of the average stock's performance can be explained by macro factors. The remaining unexplained portion we call company-specific risk (CSR). Generally, CSR is up in Healthcare (left), with all but Healthcare Supplies having a higher than median CSR vs. their own histories today, and more than half of the sub-industries in the top quartile. Managed Care has the highest CSR of any sub-industry today, with the median stock at 83%, followed by Healthcare Pharma at 78% and Biotechnology at 76% (left). The pairwise correlation (PWC) of returns has fallen for many sub-industries, meaning stocks are not particularly correlated to each other. Given the overall sector performance has been so weak, this means lots of stocks are down, but not all on the same news. The median Health Care Distributor (right) has an average pairwise correlation of 18% to its peers, the 19th percentile vs. the last 25 years.

Median Company Specific Risk for Healthcare Sub-Industries Through End-October, 2025

GICS Sub-Industry	Current CSR	CSR % Rank vs. History	CSR % Rank vs. History Since 2021
Healthcare Sector	74%	82%	95%
Managed Health Care	83%	97%	89%
Health Care Distributors	75%	91%	77%
Pharmaceuticals	78%	88%	95%
Health Care Facilities	73%	86%	98%
Health Care Technology	73%	83%	100%
Health Care Services	74%	76%	95%
Biotechnology	76%	72%	93%
Health Care Equipment	70%	71%	74%
Life Sciences Tools & Services	60%	48%	75%
Health Care Supplies	61%	22%	32%
Top 500 US Equities	61%	94%	100%
Top 3k US Equities	63%	74%	89%

Source: Trivariate Research

Median Pairwise Correlation for Healthcare Sub-Industries Through End-October, 2025

GICS Sub-Industry	Current PWC	PWC % Rank vs. History	PWC % Rank vs. History Since 2021
Healthcare Sector	21%	62%	54%
Health Care Distributors	18%	19%	33%
Health Care Services	18%	36%	36%
Health Care Technology	23%	36%	24%
Managed Health Care	34%	42%	81%
Health Care Equipment	26%	61%	54%
Biotechnology	27%	64%	55%
Pharmaceuticals	21%	65%	76%
Health Care Facilities	35%	69%	42%
Life Sciences Tools & Services	42%	80%	60%
Health Care Supplies	34%	87%	75%

Source: Trivariate Research

HAVE BIG L/S POSITIONS IN NON-REPLICABLE HIGH CSR STOCKS

In addition to CSR and PWC, simply tracking the number of stocks in each industry that are beating or lagging by 20% or more over a 12-month rolling period can provide useful information. Take Life Sciences for example (left). In August of 2025, over 80% had beaten the sub-industry average by more than 20% over the previous year. <u>This means running a portfolio sub-industry neutral within Healthcare doesn't make much sense! We think fundamental stock pickers should focus on areas with high CSR, that are hard to replicate, meaning large over-or-underweights should be in LLY, ABT, ISRG, BSX, and GILD, among others, as getting these right will help separate from the index!</u>

Life Sciences Tools & Services
% Beating or Lagging the S&P500 >20% Over Last 12m
Through End-October, 2025



Source: Trivariate Research

High Quality Healthcare Companies with High CSR and Low Replicability
Through End-October, 2025

Ticker	Company	Sub-Industry	Market Cap. (US $Bil.)	CSR
LLY	Eli Lilly and Company	Pharmaceuticals	772.59	81%
ABT	Abbott Laboratories	Health Care Equipment	214.96	73%
ISRG	Intuitive Surgical, Inc.	Health Care Equipment	189.40	66%
BSX	Boston Scientific Corporation	Health Care Equipment	149.24	78%
GILD	Gilead Sciences, Inc.	Biotechnology	148.78	77%
VRTX	Vertex Pharmaceuticals Incorporated	Biotechnology	109.11	68%
HCA	HCA Healthcare, Inc.	Health Care Facilities	104.90	82%
MCK	McKesson Corporation	Health Care Distributors	100.92	74%
REGN	Regeneron Pharmaceuticals, Inc.	Biotechnology	66.87	71%
EW	Edwards Lifesciences Corporation	Health Care Equipment	48.41	75%
VEEV	Veeva Systems Inc.	Health Care Technology	47.73	69%
INSM	Insmed Incorporated	Biotechnology	40.44	94%

Source: Trivariate Research

HEALTHCARE HAS HAD ITS WORST STRETCH IN MORE THAN 25 YEARS

For Healthcare investors, the last few years have been a particularly challenging time. **Only 24% of all Healthcare stocks have beaten the market over the last two years, up from the lowest percentage (15%) of winners posted at the end of July** (left). August 2025 was the best month for Healthcare since the middle of 2022 (right), lending some credence to the notion that the Secretary of Health and Human Services Robert F. Kennedy Jr.'s discount on the stocks has potentially moderated.

Percent of Healthcare Stocks Outperforming S&P500
24-Month Rolling Window
Through End-October, 2025



Source: Trivariate Research

Monthly Healthcare vs. Ex-Healthcare Spread
Cap. Weight Top 500 US Equities
Through End-October, 2025



Source: Trivariate Research

THE RESULT OF THE UNDERPERFORMANCE IS TROUGH VALUATION

Because the Healthcare stocks have dramatically lagged, the cap-weighted enterprise value-to-sales Healthcare vs. the rest of the market is just up off of lows and well below long-term averages (left). Similarly on relative price-to-forward earnings (right), multiples are quite suppressed. While valuation doesn't matter in isolation, if it is accompanied by above average estimate achievability, that is a potential catalyst.

Cap-Weighted EV-to-Forecast Sales
Relative Multiple, Healthcare vs. Ex-Healthcare
Growth Universe, Top 3k US Equities
Through End-October, 2025



Source: Trivariate Research

Cap-Weighted Price-to-Forward Earnings
Relative Multiple, Healthcare vs. Ex-Healthcare
Top 3k US Equities Excluding Growth
Through End-October, 2025



Source: Trivariate Research

THE BIGGEST UPWARD AND DOWNWARD REVISIONS YTD

Since the beginning of the year, ALNY, CNC, PODD, LLY, and CI have the largest 2026 upward sales revisions. ILMN, REGN, MRK, ZTS, and DHR the largest downward revisions.

Bottom and Top 10 Largest Movers, Healthcare Top 500 US Equities
YTD Estimate Revisions, Sales and Earnings
Calendar Years 2025/2026

Ticker	Company Name	Market Cap ($B)	CY 2025 Sales Revision	CY 2025 Earnings Revision	CY 2026 Sales Revision	CY 2026 Earnings Revision
ALNY	Alnylam Pharmaceuticals, Inc.	60.25	41.6%	519.0%	50.9%	152.0%
CNC	Centene Corporation	17.38	15.1%	(72.5%)	12.1%	(62.0%)
PODD	Insulet Corporation	22.03	8.6%	13.0%	11.0%	11.7%
LLY	Eli Lilly and Company	772.59	8.5%	3.9%	7.7%	7.1%
CI	The Cigna Group	65.29	8.1%	(6.7%)	6.3%	(13.2%)
HUM	Humana Inc.	33.46	7.7%	3.6%	13.6%	(4.9%)
INCY	Incyte Corporation	18.35	7.6%	12.6%	6.9%	7.0%
BSX	Boston Scientific Corporation	149.24	7.5%	9.0%	8.7%	9.4%
ELV	Elevance Health, Inc.	70.49	5.4%	(15.6%)	1.8%	(32.0%)
AMGN	Amgen Inc.	160.66	5.3%	2.1%	4.7%	3.8%
A	Agilent Technologies, Inc.	41.49	(0.3%)	(3.2%)	0.3%	(0.8%)
PFE	Pfizer Inc.	140.15	(0.4%)	5.4%	(1.6%)	2.1%
BDX	Becton, Dickinson and Company	51.22	(0.7%)	(6.5%)	(1.4%)	(6.7%)
ABT	Abbott Laboratories	214.96	(0.8%)	0.3%	(0.2%)	(0.2%)
TMO	Thermo Fisher Scientific Inc.	213.17	(1.8%)	(3.2%)	(3.7%)	(6.6%)
DHR	Danaher Corporation	152.13	(2.4%)	(9.9%)	(5.7%)	(12.6%)
ZTS	Zoetis Inc.	63.86	(2.7%)	(1.8%)	(3.5%)	(5.3%)
MRK	Merck & Co., Inc.	214.76	(3.6%)	(7.8%)	(4.1%)	(14.2%)
REGN	Regeneron Pharmaceuticals, Inc.	66.87	(3.8%)	(6.3%)	(5.2%)	(19.7%)
ILMN	Illumina, Inc.	18.88	(4.4%)	3.6%	(8.4%)	(7.7%)

Source: Trivariate Research

REVENUE GROWTH WITHOUT OPX AND INVENTORY WAS BEST

We evaluated the efficacy of over 200 signals in our data library. Growth in R&D and S&GA expense, inventory-to-sales, and 2-year forecasted sales growth were best, revenue growth acceleration, ROTE, and operating margin the worst.

Top 10 Best and Worst Signals for Healthcare Sector Year-to-Date, Rebalanced Monthly

Signal	January	February	March	April	May	June	July	August	September	October	YTD
Growth in SG&A + R&D Expense	6.4%	6.1%	(5.2%)	7.4%	2.1%	3.1%	6.3%	2.9%	3.1%	9.0%	48.6%
Inventory-to-Sales	11.1%	2.9%	5.0%	2.1%	14.5%	0.4%	(0.6%)	0.4%	7.7%	(3.0%)	46.8%
2-Year Forecast Revenue Growth	11.0%	3.8%	(3.9%)	7.8%	(2.7%)	3.4%	(4.2%)	5.8%	1.8%	9.0%	35.1%
Median YoY Revenue Growth (Last 12Q)	6.1%	5.4%	(4.0%)	6.1%	2.1%	2.0%	1.9%	4.0%	4.9%	1.1%	33.2%
SGA Growth	4.7%	1.2%	(3.9%)	8.5%	(0.9%)	3.9%	2.5%	0.4%	6.8%	5.4%	31.8%
SGA-to-Sales Acceleration	6.7%	1.1%	1.3%	2.1%	2.7%	5.4%	0.6%	5.6%	(3.1%)	5.5%	31.2%
Cash-to-Assets	5.8%	0.8%	(3.8%)	7.0%	(3.9%)	5.8%	(0.1%)	(0.4%)	8.9%	7.9%	30.6%
R&D-to-Sales	(3.6%)	0.6%	0.7%	3.3%	(4.2%)	10.7%	(2.3%)	0.7%	7.7%	14.2%	29.6%
Cash Growth	0.2%	5.2%	0.6%	4.3%	0.1%	1.3%	6.8%	6.9%	3.1%	(2.2%)	29.0%
Net Debt-to-Equity	0.0%	(1.5%)	(3.8%)	7.5%	2.1%	2.9%	5.0%	(2.9%)	5.8%	11.4%	28.7%
Price-to-Book	(7.7%)	(3.7%)	3.8%	(4.7%)	(6.6%)	(2.2%)	(3.5%)	2.3%	(1.1%)	(0.9%)	(22.2%)
ROTE Growth	(7.4%)	0.3%	8.2%	(11.5%)	(2.5%)	(5.9%)	(7.3%)	9.2%	(2.7%)	(3.1%)	(22.2%)
Price-to-Forward Earnings	(2.8%)	4.8%	8.4%	(7.4%)	0.6%	(5.8%)	(5.3%)	3.0%	(1.8%)	(16.2%)	(22.2%)
EBITDA Margin	(4.0%)	8.1%	1.2%	(5.7%)	(3.1%)	(8.3%)	5.9%	(7.5%)	1.0%	(11.6%)	(23.0%)
Price-to-EBITDA	(2.1%)	3.5%	9.8%	(9.3%)	(3.5%)	(6.1%)	(5.7%)	5.8%	(4.8%)	(11.5%)	(23.1%)
EV-to-EBITDA	(4.4%)	2.9%	10.2%	(8.3%)	(4.3%)	(7.5%)	(4.3%)	5.3%	(4.5%)	(10.3%)	(24.0%)
Forecast Net Margin	(3.1%)	7.3%	(1.6%)	(3.5%)	(2.4%)	(7.2%)	6.4%	(7.1%)	(2.5%)	(12.1%)	(24.2%)
Operating Margin	(3.7%)	6.4%	0.7%	(4.1%)	(1.5%)	(7.8%)	4.7%	(5.7%)	(3.5%)	(11.5%)	(24.3%)
ROTE	(3.2%)	6.1%	5.5%	(3.9%)	1.3%	(11.0%)	(6.7%)	(3.4%)	(5.8%)	(7.4%)	(26.2%)
Revenue Growth Acceleration	(4.8%)	(6.1%)	(1.5%)	(1.4%)	(6.2%)	(0.3%)	(5.5%)	(3.3%)	(1.8%)	(4.2%)	(30.2%)

Source: Trivariate Research

QUANTITATIVELY-DERIVED HEALTHCARE LONG IDEAS

Below we provide a list of Healthcare companies that have the highest average rank on the top 10 best performing signals in the Healthcare sector year-to-date.

Quantitatively Derived Long Ideas

Ticker	Company	Industry	Market Cap ($B)
HCA	HCA Healthcare, Inc.	Health Care Providers & Services	107.98
MCK	McKesson Corporation	Health Care Providers & Services	105.01
COR	Cencora, Inc.	Health Care Providers & Services	68.63
VEEV	Veeva Systems Inc.	Health Care Technology	48.40
CAH	Cardinal Health, Inc.	Health Care Providers & Services	46.76
HUM	Humana Inc.	Health Care Providers & Services	31.87
DXCM	DexCom, Inc.	Health Care Equipment & Supplies	23.12
PODD	Insulet Corporation	Health Care Equipment & Supplies	22.13
MEDP	Medpace Holdings, Inc.	Life Sciences Tools & Services	16.87
DOCS	Doximity, Inc.	Health Care Technology	11.99
GH	Guardant Health, Inc.	Health Care Providers & Services	11.98
HIMS	Hims & Hers Health, Inc.	Health Care Providers & Services	9.96
GMED	Globus Medical, Inc.	Health Care Equipment & Supplies	8.31
MOH	Molina Healthcare, Inc.	Health Care Providers & Services	7.70
IRTC	iRhythm Technologies, Inc.	Health Care Equipment & Supplies	5.82

Source: Trivariate Research

QUANTITATIVELY-DERIVED HEALTHCARE SHORT IDEAS

Quantitatively-derived short ideas have the lowest average rank on the top 10 performing signals in the Healthcare sector year-to-date.

Quantitatively Derived Short Ideas

Ticker	Company	Industry	Market Cap ($B)
TMO	Thermo Fisher Scientific Inc.	Life Sciences Tools & Services	213.27
DHR	Danaher Corporation	Life Sciences Tools & Services	149.89
MDT	Medtronic plc	Health Care Equipment & Supplies	115.95
A	Agilent Technologies, Inc.	Life Sciences Tools & Services	41.61
IQV	IQVIA Holdings Inc.	Life Sciences Tools & Services	35.78
STE	STERIS plc	Health Care Equipment & Supplies	23.95
ILMN	Illumina, Inc.	Life Sciences Tools & Services	18.71
ICLR	ICON Public Limited Company	Life Sciences Tools & Services	12.50
RVTY	Revvity, Inc.	Life Sciences Tools & Services	10.50
TECH	Bio-Techne Corporation	Life Sciences Tools & Services	9.33
BAX	Baxter International Inc.	Health Care Equipment & Supplies	9.23
HSIC	Henry Schein, Inc.	Health Care Providers & Services	8.54
AVTR	Avantor, Inc.	Life Sciences Tools & Services	7.90
BRKR	Bruker Corporation	Life Sciences Tools & Services	6.10
TFX	Teleflex Incorporated	Health Care Equipment & Supplies	5.51

Source: Trivariate Research

DISCLOSURES

Disclaimer

This presentation is confidential and may not be reproduced or distributed without the express prior written permission of Trivariate Research LP and its affiliates (collectively, "**Trivariate**").

The information contained herein reflects the opinions and projections of Trivariate as the date of publication, which are subject to change without notice at any time subsequent to the date of issue. Trivariate does not represent that any opinion or projection expressed herein will be realized. All information provided is for informational and research purposes only and should not be deemed as investment advice or a recommendation to purchase or sell any specific portfolio investment, security or other asset. While the information presented herein is believed to be reliable, no representation or warranty is made concerning the accuracy of any data or other information presented. Information obtained by Trivariate from third party sources in connection with the preparation of this presentation has not been independently verified by Trivariate. Additional information regarding Trivariate is available on request.

Any projections, forecasts, targets or other estimates presented herein constitute "forward-looking statements" that can be identified by the use of forward-looking terminology such as "may," "will," "should," "could," "would," "predicts," "potential," "forecasted," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," or the negatives thereof or other variations thereon or comparable terminology. Furthermore, any projections, targets, forecasts or other estimates in this presentation are "forward-looking statements" and are based upon certain assumptions that may change. Due to various risks and uncertainties, actual events or results or the actual performance of the funds may differ materially from those reflected or contemplated in such forward-looking statements. Moreover, actual events are difficult to predict and often depend upon factors that are beyond the control of the Trivariate. Nothing herein shall under any circumstances create an implication that the information contained herein is correct as of any time after the earlier of the relevant date specified herein or the date of this presentation. In addition, unless the context otherwise requires, the words "include," "includes," "including" and other words of similar import are meant to be illustrative rather than restrictive. Forward-looking statements and discussions of the business environment included herein (e.g., With respect to financial markets, business opportunities, demand, investment pipeline and other conditions) are subject to the ongoing novel coronavirus outbreak ("**COVID**" or "**COVID-19**"). The full impact of COVID-19 is particularly uncertain and difficult to predict, therefore such forward-looking statements do not reflect its ultimate potential.

This shall not constitute an offer to sell or the solicitation of an offer to buy any interests in any fund, product or account that is or may in the future be advised or managed by, Trivariate or any of its affiliates.

All data sourced from S&P Global, Bloomberg, or our Trivariate estimates. All forward-looking-statements reflect the opinion of Trivariate.